We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

HIK Hikma Pharmaceuticals Plc

-31.50 (-1.77%)
08 Dec 2023 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Hikma Pharmaceuticals Plc LSE:HIK London Ordinary Share GB00B0LCW083 ORD SHS 10P
  Price Change % Change Share Price Shares Traded Last Trade
  -31.50 -1.77% 1,751.50 661,000 16:35:01
Bid Price Offer Price High Price Low Price Open Price
1,764.00 1,764.50 1,789.00 1,761.50 1,786.00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations USD 2.52B USD 188M USD 0.8507 20.74 3.9B
Last Trade Time Trade Type Trade Size Trade Price Currency
18:48:47 O 137 1,751.46 GBX

Hikma Pharmaceuticals (HIK) Latest News

Hikma Pharmaceuticals (HIK) Discussions and Chat

Hikma Pharmaceuticals Forums and Chat

Date Time Title Posts
03/11/202300:11Hikma Pharmaceuticals1,754
13/1/201515:12 *** Hikma ***98

Add a New Thread

Hikma Pharmaceuticals (HIK) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type

Hikma Pharmaceuticals (HIK) Top Chat Posts

Top Posts
Posted at 10/12/2023 08:20 by Hikma Pharmaceuticals Daily Update
Hikma Pharmaceuticals Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker HIK. The last closing price for Hikma Pharmaceuticals was 1,783p.
Hikma Pharmaceuticals currently has 220,988,500 shares in issue. The market capitalisation of Hikma Pharmaceuticals is £3,899,342,083.
Hikma Pharmaceuticals has a price to earnings ratio (PE ratio) of 20.74.
This morning HIK shares opened at 1,786p
Posted at 30/8/2023 07:57 by robertball
Not caught by Us drug announcement yesterday re price controls...
Posted at 28/4/2023 08:13 by robertball
I'm here. This share is overlooked. Sigi's resignation was a bit of a blow and appointing an internal candidate was a vote of no confidence.It's a family firm and it might do OK in the long term.Not for speculators
Posted at 02/3/2023 19:01 by ariane
Iain Gilbert
Sharecast News
27 Feb, 2023 16:26 27 Feb, 2023 16:27

Broker tips: Hikma Pharmaceuticals

Analysts at Berenberg raised their target price on drugmaker Hikma Pharmaceuticals from 1,440.0p to 1,740.0p on Monday on the back of the group's recent trading update.

Berenberg stated that last week, Hikma reported "decent" 2022 results, in its view, with no real changes to the group's outlook from January when management presented at a competitor conference.
Posted at 02/3/2023 17:43 by waldron
RBC raises Hikma Pharma price target to 1,950 (1,750) pence - 'outperform'
Posted at 08/2/2023 13:45 by adamb1978
Share price has had a nice run over the last 3-4 months however is still very cheap if you believe it can grow at mid single digit %s which market forecasts suggest and generate the 20%-ish ROCE which it historically has.

If you believe in mean reversion and see it getting back to multiples over the last few years, this should be heading to £25-£30
Posted at 30/9/2022 09:32 by cumnor
Bought in here at £13 avg. Now the diversity nonsense is out of the way these guys (and gals I suppose) need to up the ante on their dividend payments if they wish to recover the share price.....
Posted at 15/9/2022 11:01 by swinsco
Jeffries have just cut Hik price target to 2020 from 2200 and keep it a buy rating. Broker nonsense!
Posted at 01/9/2022 10:56 by mjneish
Good to see HIK outperforming the wider market at the moment. FTSE down 1.5% at the moment, and HIK down only 1%. :)
Posted at 18/8/2022 19:32 by cumnor
Punters and IIs are tiring of indebted companies like Hikma which paid divis of 2% for past couple of years, promised the earth and fail to deliver, as recent results show. Meanwhile directors pay themselves huge salaries and bonuses but expect investors to pay dear for the measly dividend. This could have been more generous and the recent falls (not just here) in poor payers share prices reflect a change in attitude to greedy directors.
Needs to see a divi of 5% plus before I'd touch this.
Posted at 04/8/2022 09:06 by adamb1978
Even taking historic earnings, PE is only around 11x. It feels like there's a lot of negativity built into the share price here. To justify this sort of multiple, you need to believe that the business is going to be more of less flat going forwards

No investment is a sure thing, and they're all an assessment of upside and downside potential. It feels to me that the multiple provides for a lot of downside protection here, and probably far too much
Hikma Pharmaceuticals share price data is direct from the London Stock Exchange

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 |